Our Publications

For two decades, the PHICOR team has been developing and utilizing computer and systems approaches, methods, models, and tools to help decision makers better understand and address complex systems in health and public health. The PHICOR team has published over 255 publications in scientific peer-reviewed journals. PHICOR’s research over the past two decades involves working directly with those making decisions in various aspects of health.

Sarah Rebbert 3/1/21 Sarah Rebbert 3/1/21

How long-term acute care hospitals (LTACHs) can play an important role in controlling carbapenem-resistant enterobacteriaceae (CRE) in a region: A simulation modeling study

How long-term acute care hospitals (LTACHs) can play an important role in controlling carbapenem-resistant enterobacteriaceae (CRE) in a region: A simulation modeling study

BH 2/1/21 BH 2/1/21

How to choose target facilities in a region to implement carbapenem-resistant Enterobacteriaceae (CRE) control measures

How to choose target facilities in a region to implement carbapenem-resistant Enterobacteriaceae (CRE) control measures

Sarah Rebbert 11/1/20 Sarah Rebbert 11/1/20

Economic value of Acinetobacter baumannii screening in the intensive care unit (ICU)

Economic value of Acinetobacter baumannii screening in the intensive care unit (ICU)

Sarah Rebbert 6/1/20 Sarah Rebbert 6/1/20

Knowing more of the iceberg: How detecting a greater proportion of carbapenem-resistant Enterobacteriaceae (CRE) carriers impacts transmission

Knowing more of the iceberg: How detecting a greater proportion of carbapenem-resistant Enterobacteriaceae (CRE) carriers impacts transmission

Sarah Rebbert 3/1/20 Sarah Rebbert 3/1/20

How introducing a registry with automated alerts for carbapenem-resistant Enterobacteriaceae (CRE) may help control CRE spread in a region

How introducing a registry with automated alerts for carbapenem-resistant Enterobacteriaceae (CRE) may help control CRE spread in a region

Sarah Rebbert 11/1/19 Sarah Rebbert 11/1/19

The economic value of screening hemodialysis patients for methicillin-resistant Staphylococcus aureus (MRSA) in the United States

The economic value of screening hemodialysis patients for methicillin-resistant Staphylococcus aureus (MRSA) in the United States

Sarah Rebbert 5/1/19 Sarah Rebbert 5/1/19

Epidemiologic and economic impact of methicillin-resistant Staphylococcus aureus in obstetrics

Epidemiologic and economic impact of methicillin-resistant Staphylococcus aureus in obstetrics

Sarah Rebbert 3/28/19 Sarah Rebbert 3/28/19

Tracking the spread of carbapenem-resistant enterobacteriaceae (CRE) through clinical cultures alone underestimates the spread of CRE even more than anticipated

Tracking the spread of carbapenem-resistant enterobacteriaceae (CRE) through clinical cultures alone underestimates the spread of CRE even more than anticipated

Sarah Rebbert 2/11/19 Sarah Rebbert 2/11/19

The SHIELD Orange County project -multi drug- resistant organism (MDRO) prevalence in 21 nursing homes and long term acute care facilities in southern California

Sarah Rebbert 1/1/19 Sarah Rebbert 1/1/19

The potential effects of introducing microneedle patch vaccines into routine vaccine supply chain

Sarah Rebbert 10/9/18 Sarah Rebbert 10/9/18

The impact of healthcare-associated methicillin-resistant Staphylococcus aureus infections on post-discharge costs and utilization

The impact of healthcare-associated methicillin-resistant Staphylococcus aureus infections on post-discharge costs and utilization

Sarah Rebbert 3/19/18 Sarah Rebbert 3/19/18

The economic value of the Centers for Disease Control and Prevention (CDC) Carbapenem-Resistant Enterobacteriaceae (CRE) toolkit

The economic value of the Centers for Disease Control and Prevention (CDC) Carbapenem-Resistant Enterobacteriaceae (CRE) toolkit

Sarah Rebbert 10/24/16 Sarah Rebbert 10/24/16

Impact of delays between the Clinical and Laboratory Standards Institute (CLSI) and the Food and Drug Administration (FDA)

Impact of delays between the Clinical and Laboratory Standards Institute (CLSI) and the Food and Drug Administration (FDA) revising interpretive criteria for Carbapenem-Resistant Enterobacteriaceae (CRE)

Sarah Rebbert 9/15/16 Sarah Rebbert 9/15/16

Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States

Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States

Sarah Rebbert 3/1/16 Sarah Rebbert 3/1/16

Beyond the Intensive Care Unit (ICU): Countywide impact of universal ICU Staphylococcus aureus decolonization

Beyond the Intensive Care Unit (ICU): Countywide impact of universal ICU Staphylococcus aureus decolonization

BH 3/1/16 BH 3/1/16

The potential trajectory of carbapenem-resistant enterobacteriaceae, an emerging threat to health-care facilities, and the impact of the Centers for Disease Control (CDC) and prevention toolkit

The potential trajectory of carbapenem-resistant enterobacteriaceae, an emerging threat to health-care facilities, and the impact of the Centers for Disease Control (CDC) and prevention toolkit

Sarah Rebbert 9/21/15 Sarah Rebbert 9/21/15

Quantifying the exposure to antibiotic-resistant pathogens among patients discharges from a single hospital across all California healthcare facilities

Sarah Rebbert 8/7/15 Sarah Rebbert 8/7/15

Vital signs: Estimated effects of a coordinated approach for action to reduce antibiotic-resistant infections in Health Care facilities